Prostate Cancer Immunology: Biology, Therapeutics, and Challenges
- 10 November 2005
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (32) , 8262-8269
- https://doi.org/10.1200/jco.2005.03.4595
Abstract
A number of recently developed and promising approaches to antitumoral immunotherapy are being investigated as potential treatments for advanced prostate cancer. These approaches largely revolve around strategies to increase antigen-specific T-cell activation against prostate tumors as well as precise manipulations of critical co-regulatory receptors that help to maintain and prolong the activity of antigen-presenting cells and T cells that are capable of mediating tumor regression. Herein, we describe the experience with the most recent and promising approaches pertaining to prostate cancer immunotherapy. Additionally, we discuss the mechanistic basis for these approaches as well as current limitations that must still be addressed in order to propel immunotherapy into the forefront of prostate cancer treatment.Keywords
This publication has 46 references indexed in Scilit:
- Versatile Prostate Cancer Treatment with Inducible Caspase and Interleukin-12Cancer Research, 2005
- Recent clinical development of dendritic cell-based immunotherapy for prostate cancerExpert Opinion on Biological Therapy, 2004
- LAPAROSCOPIC PARTIAL NEPHRECTOMY AND PROSTATECTOMY: WEIGHING THE COSTS AND THE BENEFITSJournal of Urology, 2004
- Correlation Between Glomerular Size and Long-Term Renal Function in Patients with Substantial Loss of Renal MassJournal of Urology, 2003
- Dendritic cells transfected with interleukin‐12 and pulsed with tumor extract inhibit growth of murine prostatic carcinoma in vivoThe Prostate, 2003
- Prostate-Specific Antigen Response and Systemic T Cell Activation After In Situ Gene Therapy in Prostate Cancer Patients Failing RadiotherapyHuman Gene Therapy, 2001
- Local Intratumoral Tumor Necrosis Factor-α and Systemic IFN-α2b in Patients with Locally Advanced Prostate CancerJournal of Interferon & Cytokine Research, 2001
- GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trialThe Prostate, 1999
- Enhancement of Antitumor Immunity by CTLA-4 BlockadeScience, 1996
- Histological grade, perineural infiltration, tumour-infiltrating lymphocytes and apoptosis as determinants of long-term prognosis in prostatic adenocarcinomaEuropean Journal Of Cancer, 1994